Results 241 to 250 of about 188,791 (289)
Some of the next articles are maybe not open access.
Zeitschrift für Rheumatologie, 2010
Rituximab as a monoclonal antibody against CD20 was approved for treatment of patients with rheumatoid arthritis (RA) with inadequate response to or contraindication for the use of a TNF blocker. This article focuses on current results from clinical trials at different developmental stages as well as from registry data in anti-TNF non-responders ...
E, Feist, T, Dörner
openaire +3 more sources
Rituximab as a monoclonal antibody against CD20 was approved for treatment of patients with rheumatoid arthritis (RA) with inadequate response to or contraindication for the use of a TNF blocker. This article focuses on current results from clinical trials at different developmental stages as well as from registry data in anti-TNF non-responders ...
E, Feist, T, Dörner
openaire +3 more sources
Drugs of Today, 2005
Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule on the B-cell surface. It is the first antibody of its kind to be licensed for the treatment of non-Hodgkin's lymphoma. Rituximab was found to be effective, well-tolerated and has a good safety profile, though its precise cellular effects are still not well understood. Rituximab
Tanya, Doan, Elena, Massarotti
openaire +2 more sources
Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule on the B-cell surface. It is the first antibody of its kind to be licensed for the treatment of non-Hodgkin's lymphoma. Rituximab was found to be effective, well-tolerated and has a good safety profile, though its precise cellular effects are still not well understood. Rituximab
Tanya, Doan, Elena, Massarotti
openaire +2 more sources
Drugs, 1999
Rituximab is a chimaeric monoclonal antibody which specifically binds to the CD20 antigen on normal and malignant B lymphocytes. It produces antibody-dependent cell- and complement-mediated cytotoxicity in these cells. Rituximab reduced peripheral B lymphocyte counts by approximately 90% within 3 days in patients with relapsed indolent lymphoma. Counts
S V, Onrust, H M, Lamb, J A, Balfour
openaire +2 more sources
Rituximab is a chimaeric monoclonal antibody which specifically binds to the CD20 antigen on normal and malignant B lymphocytes. It produces antibody-dependent cell- and complement-mediated cytotoxicity in these cells. Rituximab reduced peripheral B lymphocyte counts by approximately 90% within 3 days in patients with relapsed indolent lymphoma. Counts
S V, Onrust, H M, Lamb, J A, Balfour
openaire +2 more sources
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy [PDF]
New England Journal of Medicine, 2019 Fernando C Fervenza +2 more
exaly +2 more sources
European Journal of Neurology, 2004
Chemotherapy has been used for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with incosistent results. Chemotheraphy has been used for treating with inconsistent results. Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen, used to treat B‐cell lymphoma and reported to be effective in some ...
BRIANI, CHIARA +5 more
openaire +3 more sources
Chemotherapy has been used for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with incosistent results. Chemotheraphy has been used for treating with inconsistent results. Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen, used to treat B‐cell lymphoma and reported to be effective in some ...
BRIANI, CHIARA +5 more
openaire +3 more sources